Tags

Type your tag names separated by a space and hit enter

Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies.
Menopause. 2018 10; 25(10):1155-1164.M

Abstract

OBJECTIVES

To perform a meta-analysis on the global prevalence of metabolic syndrome (MetS) in postmenopausal women. The meta-analysis also sought to measure the relationship menopause status has with MetS and its components.

METHODS

The Web of Science, Medline, PubMed, Scopus, Embase, CINAHL, DOAJ, and Google Scholar were all searched using the relevant keywords. Articles published during the period 2004 to 2017 that met our inclusion criteria and reported the prevalence of MetS among premenopausal and postmenopausal women were included. In the presence of heterogeneity, random-effects models were used to pool the prevalence and odds ratios (ORs), as measures of association in cross-sectional and comparative cross-sectional studies, respectively.

RESULTS

The prevalence of MetS among postmenopausal women (119 studies [n = 95,115]) and the OR comparing the prevalence of MetS among postmenopausal and premenopausal women (23 studies [n = 66,801]) were pooled separately. The pooled prevalence of MetS among postmenopausal women was found to be 37.17% (95% confidence interval [CI] 35.00%-39.31%), but varied from 13.60% (95% CI 13.55%-13.64%) to 46.00% (95% CI 1.90%-90.09%), depending upon the diagnostic criteria used. The overall pooled OR for MetS in postmenopausal women, compared with premenopausal women, was OR 3.54 (95% CI 2.92-4.30), but this ranged from OR 2.74 (95% CI 1.32-5.66) to OR 5.03 (95% CI 2.25-11.22), depending upon the criteria used. Furthermore, the odds of high fasting blood sugar (OR 3.51, 95% CI 2.11-5.83), low high-density lipoprotein cholesterol (OR 1.45, 95% CI 1.03-2.03), high blood pressure (OR 3.95, 95% CI 2.01-7.78), high triglycerides (OR 3.2, 95% CI 2.37-4.31), and high waist circumference (OR 2.75, 95% CI 1.80-4.21) were all found to be higher in postmenopausal women than in premenopausal women.

CONCLUSIONS

The prevalence of MetS is relatively high in postmenopausal women and was more prevalent among postmenopausal than premenopausal women. Menopausal hormone therapy should be used with caution in patients with MetS, as its safety has not yet been evaluated among MetS patients and meticulous evaluation of each individual patient before starting MHT is needed.

Authors+Show Affiliations

Managerial Epidemiology Research Center, Department of Public Health, School of Nursing and Midwifery, Maragheh University of Medical Sciences, Maragheh, Iran.Department of Epidemiology and Biostatistics, Faculty of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Nutrition Research Center, Department of Biochemistry and Diet Therapy, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.Department of Epidemiology and Reproductive Health, Reproductive Epidemiology Research Centre, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.Department of Community Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.Department of Epidemiology, Faculty of Health, Ilam University of Medical Sciences, Ilam, Iran.Managerial Epidemiology Research Center, Department of Public Health, School of Nursing and Midwifery, Maragheh University of Medical Sciences, Maragheh, Iran.Middle East Technical University, Northern Cyprus Campus, Güzelyurt/Morphou, Northern Cyprus.Managerial Epidemiology Research Center, Department of Public Health, School of Nursing and Midwifery, Maragheh University of Medical Sciences, Maragheh, Iran. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review

Language

eng

PubMed ID

29787477

Citation

Hallajzadeh, Jamal, et al. "Metabolic Syndrome and Its Components in Premenopausal and Postmenopausal Women: a Comprehensive Systematic Review and Meta-analysis On Observational Studies." Menopause (New York, N.Y.), vol. 25, no. 10, 2018, pp. 1155-1164.
Hallajzadeh J, Khoramdad M, Izadi N, et al. Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies. Menopause. 2018;25(10):1155-1164.
Hallajzadeh, J., Khoramdad, M., Izadi, N., Karamzad, N., Almasi-Hashiani, A., Ayubi, E., Qorbani, M., Pakzad, R., Hasanzadeh, A., Sullman, M. J. M., & Safiri, S. (2018). Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies. Menopause (New York, N.Y.), 25(10), 1155-1164. https://doi.org/10.1097/GME.0000000000001136
Hallajzadeh J, et al. Metabolic Syndrome and Its Components in Premenopausal and Postmenopausal Women: a Comprehensive Systematic Review and Meta-analysis On Observational Studies. Menopause. 2018;25(10):1155-1164. PubMed PMID: 29787477.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies. AU - Hallajzadeh,Jamal, AU - Khoramdad,Maliheh, AU - Izadi,Neda, AU - Karamzad,Nahid, AU - Almasi-Hashiani,Amir, AU - Ayubi,Erfan, AU - Qorbani,Mostafa, AU - Pakzad,Reza, AU - Hasanzadeh,Amir, AU - Sullman,Mark J M, AU - Safiri,Saeid, PY - 2018/5/23/pubmed PY - 2019/10/23/medline PY - 2018/5/23/entrez SP - 1155 EP - 1164 JF - Menopause (New York, N.Y.) JO - Menopause VL - 25 IS - 10 N2 - OBJECTIVES: To perform a meta-analysis on the global prevalence of metabolic syndrome (MetS) in postmenopausal women. The meta-analysis also sought to measure the relationship menopause status has with MetS and its components. METHODS: The Web of Science, Medline, PubMed, Scopus, Embase, CINAHL, DOAJ, and Google Scholar were all searched using the relevant keywords. Articles published during the period 2004 to 2017 that met our inclusion criteria and reported the prevalence of MetS among premenopausal and postmenopausal women were included. In the presence of heterogeneity, random-effects models were used to pool the prevalence and odds ratios (ORs), as measures of association in cross-sectional and comparative cross-sectional studies, respectively. RESULTS: The prevalence of MetS among postmenopausal women (119 studies [n = 95,115]) and the OR comparing the prevalence of MetS among postmenopausal and premenopausal women (23 studies [n = 66,801]) were pooled separately. The pooled prevalence of MetS among postmenopausal women was found to be 37.17% (95% confidence interval [CI] 35.00%-39.31%), but varied from 13.60% (95% CI 13.55%-13.64%) to 46.00% (95% CI 1.90%-90.09%), depending upon the diagnostic criteria used. The overall pooled OR for MetS in postmenopausal women, compared with premenopausal women, was OR 3.54 (95% CI 2.92-4.30), but this ranged from OR 2.74 (95% CI 1.32-5.66) to OR 5.03 (95% CI 2.25-11.22), depending upon the criteria used. Furthermore, the odds of high fasting blood sugar (OR 3.51, 95% CI 2.11-5.83), low high-density lipoprotein cholesterol (OR 1.45, 95% CI 1.03-2.03), high blood pressure (OR 3.95, 95% CI 2.01-7.78), high triglycerides (OR 3.2, 95% CI 2.37-4.31), and high waist circumference (OR 2.75, 95% CI 1.80-4.21) were all found to be higher in postmenopausal women than in premenopausal women. CONCLUSIONS: The prevalence of MetS is relatively high in postmenopausal women and was more prevalent among postmenopausal than premenopausal women. Menopausal hormone therapy should be used with caution in patients with MetS, as its safety has not yet been evaluated among MetS patients and meticulous evaluation of each individual patient before starting MHT is needed. SN - 1530-0374 UR - https://www.unboundmedicine.com/medline/citation/29787477/Metabolic_syndrome_and_its_components_in_premenopausal_and_postmenopausal_women:_a_comprehensive_systematic_review_and_meta_analysis_on_observational_studies_ L2 - https://doi.org/10.1097/GME.0000000000001136 DB - PRIME DP - Unbound Medicine ER -